Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IXHL Stock Forecast 2026-2027
$3.65
Current Price
$51.00M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IXHL Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
IXHL Price Momentum
+17.0%
1 Week Change
+17.7%
1 Month Change
-79.7%
1 Year Change
-66.0%
Year-to-Date Change
-92.7%
From 52W High of $49.80
+52.1%
From 52W Low of $2.40
📊 TOP ANALYST CALLS
Did IXHL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Incannex is one of their latest high-conviction picks.
Latest IXHL Stock Price Targets & Analyst Predictions
IXHL has shown a year-to-date change of -66.0% and a 1-year change of -79.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for IXHL. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IXHL Analyst Ratings
0
Buy
0
Hold
0
Sell
IXHL Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.65
Latest IXHL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IXHL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 8, 2022 | Mizuho | Neutral | Maintains | $N/A | |
| Nov 16, 2022 | Keybanc | Sector Weight | Downgrade | $N/A | |
| Nov 3, 2022 | Mizuho | Neutral | Downgrade | $N/A | |
| Nov 3, 2022 | Truist Securities | Hold | Downgrade | $N/A | |
| Nov 3, 2022 | Raymond James | Outperform | Maintains | $N/A | |
| Nov 3, 2022 | RBC Capital | Outperform | Maintains | $N/A | |
| Nov 3, 2022 | Barclays | Overweight | Maintains | $N/A | |
| Oct 24, 2022 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Oct 24, 2022 | Truist Securities | Buy | Maintains | $N/A | |
| Oct 24, 2022 | Keybanc | Overweight | Maintains | $N/A | |
| Oct 24, 2022 | RBC Capital | Outperform | Maintains | $N/A | |
| Oct 21, 2022 | Needham | Hold | Downgrade | $N/A | |
| Oct 17, 2022 | Mizuho | Buy | Maintains | $N/A | |
| Oct 11, 2022 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Sep 23, 2022 | BTIG | Neutral | Initiates | $N/A | |
| Aug 4, 2022 | Mizuho | Buy | Maintains | $N/A | |
| Aug 4, 2022 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Aug 4, 2022 | Raymond James | Outperform | Maintains | $N/A | |
| Aug 4, 2022 | Needham | Buy | Maintains | $N/A | |
| Aug 1, 2022 | RBC Capital | Outperform | Maintains | $N/A |
Incannex Healthcare Inc. (IXHL) Competitors
The following stocks are similar to Incannex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IXHL
Incannex Healthcare
mkt cap
51.00M
Incannex Healthcare Inc. (IXHL) Financial Data
Incannex Healthcare Inc. has a market capitalization of $51.00M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -130.4%.
Valuation Metrics
Market Cap
$51.00M
Enterprise Value
$-25,140,264
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+158.0%
Current Ratio
48.3x
Debt/Equity
0.2x
ROE
-130.4%
ROA
-37.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Incannex Healthcare Inc. (IXHL) Business Model
About Incannex Healthcare Inc.
What They Do
Develops novel therapies for chronic conditions.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, focusing on the research and development of innovative oral fixed-dose combination therapies. It generates revenue through the advancement of its drug candidates, which target chronic conditions and aim to address unmet medical needs, potentially leading to partnerships or sales upon successful clinical trials and regulatory approvals.
Additional Information
Founded in 2001 and based in Sydney, Australia, Incannex Healthcare emphasizes reducing individual drug dosages to minimize side effects while enhancing therapeutic efficacy. Its lead candidates address conditions such as obstructive sleep apnea, generalized anxiety disorder, and various inflammatory diseases, positioning the company in the growing specialty drug manufacturing sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
12
CEO
Mr. Joel Bradley Latham
Country
Australia
IPO Year
2022
Website
www.incannex.comIncannex Healthcare Inc. (IXHL) Latest News & Analysis
Latest News
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
23 days ago
Quick Summary
The board has resumed buyback activity after a pause, executing repurchases over the last two trading days.
Why It Matters
Share buybacks can signal management's confidence in the company's value and may improve earnings per share, potentially boosting stock prices and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
25 days ago
Quick Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has partnered with the AASM Foundation to sponsor a grant for research on sleep apnea, to be awarded in 2026.
Why It Matters
Incannex's partnership with AASM enhances its credibility in sleep medicine, potentially boosting market interest and driving future growth in a lucrative healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Incannex Healthcare (Nasdaq: IXHL) reported $75 million in cash and no debt after recent financing, while its market cap is $46 million, indicating a negative enterprise value.
Why It Matters
Incannex's $75 million cash and no debt contrast sharply with its $46 million market cap, indicating potential undervaluation and possible investment opportunities or risks.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has regained compliance with Nasdaq's minimum bid price requirement, maintaining a closing price of $1.00 or greater for 11 consecutive days.
Why It Matters
Regaining compliance with Nasdaq's minimum bid price enhances Incannex Healthcare's market credibility, potentially attracting more investors and stabilizing its stock price.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment
1 month ago
Quick Summary
Incannex Healthcare Limited (NASDAQ: IXHL) shares declined after the company announced a registered direct offering of $10 million.
Why It Matters
The $10 million direct offering dilutes existing shares, signaling potential cash flow issues, which may lead to reduced investor confidence and a decline in share value.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Incannex Healthcare Inc. will issue 2 million shares and warrants at $5.00 per share, raising $10 million. If warrants are fully exercised, total proceeds could reach $23 million. Closing expected March 13, 2026.
Why It Matters
Incannex Healthcare's $10 million financing could enhance its liquidity and support ongoing development, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IXHL Stock
What is Incannex Healthcare Inc.'s (IXHL) stock forecast for 2026?
Analyst forecasts for Incannex Healthcare Inc. (IXHL) are not currently available. The stock is trading at $3.65.
Is IXHL stock a good investment in 2026?
Analyst ratings for IXHL are not currently available. The stock is currently trading at $3.65. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IXHL stock?
Price predictions from Wall Street analysts for IXHL are not currently available. The stock is trading at $3.65.
What is Incannex Healthcare Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on the research and development of innovative oral fixed-dose combination therapies. It generates revenue through the advancement of its drug candidates, which target chronic conditions and aim to address unmet medical needs, potentially leading to partnerships or sales upon successful clinical trials and regulatory approvals.
What is the highest forecasted price for IXHL Incannex Healthcare Inc.?
Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $3.65.
What is the lowest forecasted price for IXHL Incannex Healthcare Inc.?
Price targets from Wall Street analysts for IXHL are not currently available. The stock is trading at $3.65.
What is the overall IXHL consensus from analysts for Incannex Healthcare Inc.?
Analyst ratings for IXHL are not currently available. The stock is trading at $3.65.
How accurate are IXHL stock price projections?
Stock price projections, including those for Incannex Healthcare Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 5:32 PM UTC